Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance
Conditions
Interventions
Omecamtiv Mecarbil
Placebo
Locations
81
United States
Alaska Heart and Vascular Institute
Anchorage, Alaska, United States
Arkansas Cardiology Clinic
Little Rock, Arkansas, United States
Harbor-UCLA Medical Center
Torrance, California, United States
South Denver Cardiology Associates, PC
Littleton, Colorado, United States
Hartford Hospital-University of Connecticut School of Medicine
Hartford, Connecticut, United States
Holy Cross Hospital - Fort Lauderdale
Fort Lauderdale, Florida, United States
Start Date
April 9, 2019
Primary Completion Date
November 8, 2021
Completion Date
January 6, 2022
Last Updated
March 7, 2023
NCT07057466
NCT06229678
NCT06859970
NCT06479876
NCT06964464
NCT06369298
Lead Sponsor
Cytokinetics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions